Skip to main content
SpringerLink
Log in

Risk-stratified DMARD tapering feasible in RA, reduces costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hagen M, et al. Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission. 18th Annual Congress of the European League Against Rheumatism : abstr. OP0249, 14 Jun 2017. Available from: URL: https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=358578.

  2. EULAR Press Office. NEW RELAPSE PREDICTION TOOL REDUCES COST OF RHEUMATOID ARTHRITIS TREATMENT. Internet Document : 16 Jun 2017. Available from: URL: https://www.eular.org/congresspressreleases/New_relapse_prediction_tool_reduces_cost_of_rheumatoid_arthritis_treatment__OP0249.pdf.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk-stratified DMARD tapering feasible in RA, reduces costs. PharmacoEcon Outcomes News 781, 30 (2017). https://doi.org/10.1007/s40274-017-4122-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4122-5

Search

Navigation